4.6 Review

Management of hepatitis C virus genotype 4

期刊

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
卷 19, 期 11, 页码 1233-1239

出版社

WILEY
DOI: 10.1111/j.1440-1746.2003.03325.x

关键词

chronic hepatitis; interferon; pegylated; ribavirin; therapy

向作者/读者索取更多资源

Hepatitis C virus (HCV) genotype 4 is predominantly found in the Middle East and North Africa. Because most of the large randomized controlled trials of antiviral therapy for chronic hepatitis C were conducted in North America and Europe, little is known about management of patients with this particular genotype. Based on the available data, sustained virological response rates to interferon-based therapies appear to be intermediate between the relatively resistant HCV genotype I and the readily responsive genotypes 2 and 3. Several large prospective studies of pegylated interferon plus ribavirin combination therapy, the current gold-standard treatment, have recently been completed and will be reviewed. (C) 2004 Blackwell Publishing Asia Pry Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据